NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the U.S. Preventive Services Task Force
Evidence Synthesis, No. 226
Investigators: Daniel E. Jonas, MD, MPH, Sean Riley, MA, MSc, Lindsey Lee, PharmD, Cory Coffey, PharmD, BCACP, BCPP, Shu-Hua Wang, MD, PharmD, MPH&TM, FIDSA, Gary N. Asher, MD, MPH, Anne Berry, MD, Niketa Williams, MD, MS, Casey Balio, PhD, Christiane E. Voisin, MSLS, and Leila Kahwati, MD, MPH.
Structured Abstract
Purpose:
To review the evidence on benefits and harms of screening for and treatment of latent tuberculosis infection (LTBI) for adult populations and settings relevant to primary care in the United States.
Data Sources:
PubMed/MEDLINE, the Cochrane Library, and trial registries through December 3, 2021; reference lists of retrieved articles; outside experts; and reviewers, with surveillance of the literature through January 20, 2023.
Study Selection:
English-language controlled studies evaluating (1) screening for LTBI with the tuberculin skin test (TST) using the Mantoux method or commercial interferon-gamma release assays (IGRAs) or (2) treatment of LTBI with pharmacotherapy regimens that are currently recommended by the Centers for Disease Control and Prevention. We excluded studies of close contacts of persons with active tuberculosis (TB) because testing and treatment of such populations is considered part of contact tracing for public health as opposed to a primary care function. We excluded studies of persons with underlying immunosuppression and for whom LTBI testing is considered part of standard disease management (e.g., persons with the human immunodeficiency virus, planned or active use of targeted immune modulators).
Data Extraction:
One investigator extracted data and a second checked accuracy. Two reviewers independently rated quality for all included studies using predefined criteria.
Data Synthesis:
This review included 113 publications (69,009 participants); 101 of those assessed screening test accuracy or reliability. No studies evaluated benefits and harms of screening compared with no screening. Pooled estimates for sensitivity of the TST at the 5-mm and 10-mm induration thresholds for positivity were 0.80 (95% confidence interval [CI], 0.74 to 0.87) and 0.81 (95% CI, 0.76 to 0.87), respectively. The pooled estimate at the 15-mm threshold was 0.60 (95% CI, 0.46 to 0.74). Pooled estimates for sensitivity of IGRA tests ranged from 0.81 (95% CI, 0.79 to 0.84) for the QuantiFERON-TB Gold-In-Tube® test (3rd-generation test) to 0.90 (95% CI, 0.87 to 0.92) for T-SPOT.TB. Pooled estimates for specificity of screening tests ranged from 0.95 to 0.99. For treatment of LTBI, a large (N=27,830) good-quality randomized, controlled trial (RCT) found a relative risk (RR) for progression to active TB at 5 years of 0.35 (95% CI, 0.24 to 0.52) for 24 weeks of isoniazid compared with placebo (N=13,955; number needed to treat, 112). Our sensitivity analyses adding four RCTs that did not meet all of our eligibility criteria (e.g., using a longer duration of treatment than currently recommended) found an RR of 0.31 (95% CI, 0.24 to 0.41; 5 RCTs; N=36,823). A previously published network metaanalysis reported that multiple regimens were efficacious compared with placebo or no treatment, including isoniazid regimens of 6 months (odds ratio [OR], 0.65 [95% credible interval [CrI], 0.50 to 0.83] vs. placebo) or longer, rifampin plus isoniazid regimens of 3 to 4 months (OR, 0.53 [CrI, 0.36 to 0.78] vs. placebo), and weekly rifapentine plus isoniazid regimens (OR, 0.36 [CrI, 0.18 to 0.73] vs. no treatment). For harms, a large (N=27,830) good-quality RCT reported an RR for hepatotoxicity of 4.59 (95% CI, 2.03 to 10.39; number needed to harm, 279) for 24 weeks of isoniazid compared with placebo. Our sensitivity analyses adding three RCTs that did not meet all of our eligibility criteria (e.g., longer duration of isoniazid) yielded a similar result (pooled RR, 5.04 [95% CI, 2.50 to 10.15]; 4 RCTs; N=35,161). Our meta-analyses found greater risk for hepatotoxicity with isoniazid than with rifampin (pooled RR, 4.22 [95% CI, 2.21 to 8.06], N=7,339).
Limitations:
Tests for the direct diagnosis of LTBI are not available. Thus, studies estimated accuracy using patients with confirmed active TB to establish sensitivity and healthy, low-risk persons to establish specificity. The applicability to other populations is somewhat uncertain. The single placebo-controlled trial meeting all eligibility criteria that established the effectiveness of isoniazid for preventing active TB was published more than 40 years ago and was conducted among subjects with pulmonary fibrotic lesions; it may overestimate the benefits of treatment for populations with lower risk for progression. Contemporary treatment studies have not included placebo arms; benefits and harms of newer treatments were estimated from comparative studies.
Conclusions:
No studies evaluated the benefits and harms of screening for LTBI compared with no screening. TST and IGRAs are moderately sensitive and highly specific. Treatment of LTBI with recommended regimens reduces the risk of progression to active TB. Isoniazid is associated with higher rates of hepatotoxicity than placebo or rifampin.
Contents
Suggested citation:
Jonas DE, Riley S, Lee L, Coffey C, Wang SH, Asher G, Berry A, Williams N, Balio C, Voisin CE, Kahwati L. Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 226. AHRQ Publication No. 22-05298-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2023.
This report is based on research conducted by the RTI International–University of North Carolina at Chapel Hill Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (75Q80120D00007, Task Order No. 75Q80120F32001). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.
The information in this report is intended to help healthcare decision makers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of healthcare services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
- NLM CatalogRelated NLM Catalog Entries
- Review Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the U.S. Preventive Services Task ForceKahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, Weber RP, Jonas DE. 2016 Sep
- Review Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.[JAMA. 2016]Review Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, Weber RP, Jonas DE. JAMA. 2016 Sep 6; 316(9):970-83.
- Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.[JAMA. 2023]Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.Jonas DE, Riley SR, Lee LC, Coffey CP, Wang SH, Asher GN, Berry AM, Williams N, Balio C, Voisin CE, et al. JAMA. 2023 May 2; 329(17):1495-1509.
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.[Cochrane Database Syst Rev. 2022]Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, et al. Cochrane Database Syst Rev. 2022 Feb 1; 2(2022). Epub 2022 Feb 1.
- Review Screening for Depression, Anxiety, and Suicide Risk in Children and Adolescents: An Evidence Review for the U.S. Preventive Services Task Force[ 2022]Review Screening for Depression, Anxiety, and Suicide Risk in Children and Adolescents: An Evidence Review for the U.S. Preventive Services Task ForceViswanathan M, Wallace I, Middleton JC, Kennedy SM, McKeeman J, Hudson K, Rains C, Vander Schaaf EB, Kahwati L. 2022 Oct
- Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for th...Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the U.S. Preventive Services Task Force
Your browsing activity is empty.
Activity recording is turned off.
See more...